288 related articles for article (PubMed ID: 28688687)
1. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer.
Wendrich AW; Swartz JE; Bril SI; Wegner I; de Graeff A; Smid EJ; de Bree R; Pothen AJ
Oral Oncol; 2017 Aug; 71():26-33. PubMed ID: 28688687
[TBL] [Abstract][Full Text] [Related]
2. The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin.
Bril SI; Al-Mamgani A; Chargi N; Remeijer P; Devriese LA; de Boer JP; de Bree R
Head Neck; 2022 Jan; 44(1):189-200. PubMed ID: 34713519
[TBL] [Abstract][Full Text] [Related]
3. The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy.
Huiskamp LFJ; Chargi N; Devriese LA; de Jong PA; de Bree R
Eur Arch Otorhinolaryngol; 2020 Oct; 277(10):2847-2858. PubMed ID: 32335709
[TBL] [Abstract][Full Text] [Related]
4. Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol.
Schaeffers AWMA; Devriese LA; van Gils CH; Dankbaar JW; Voortman J; de Boer JP; Slingerland M; Hendriks MP; Smid EJ; Frederix GWJ; de Bree R
PLoS One; 2023; 18(11):e0294147. PubMed ID: 38011186
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer.
Jung AR; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Oral Oncol; 2019 Aug; 95():95-99. PubMed ID: 31345401
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Skeletal Muscle Depletion on Head and Neck Squamous Cell Carcinoma.
Nishikawa D; Hanai N; Suzuki H; Koide Y; Beppu S; Hasegawa Y
ORL J Otorhinolaryngol Relat Spec; 2018; 80(1):1-9. PubMed ID: 29393251
[TBL] [Abstract][Full Text] [Related]
7. Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer.
Chargi N; Bashiri F; Wendrich AW; Smid EJ; de Jong PA; Huitema ADR; Devriese LA; de Bree R
Eur Arch Otorhinolaryngol; 2022 Jul; 279(7):3685-3694. PubMed ID: 35038029
[TBL] [Abstract][Full Text] [Related]
8. The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study.
Chargi N; Molenaar-Kuijsten L; Huiskamp LFJ; Devriese LA; de Bree R; Huitema ADR
Eur J Cancer; 2022 Jan; 160():92-99. PubMed ID: 34810046
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients.
Swartz JE; Pothen AJ; Wegner I; Smid EJ; Swart KM; de Bree R; Leenen LP; Grolman W
Oral Oncol; 2016 Nov; 62():28-33. PubMed ID: 27865369
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia and its impact in head and neck cancer treatment.
de Bree R; van Beers MA; Schaeffers AWMA
Curr Opin Otolaryngol Head Neck Surg; 2022 Apr; 30(2):87-93. PubMed ID: 35255045
[TBL] [Abstract][Full Text] [Related]
11. Skeletal muscle mass at C3 may not be a strong predictor for skeletal muscle mass at L3 in sarcopenic patients with head and neck cancer.
Yoon JK; Jang JY; An YS; Lee SJ
PLoS One; 2021; 16(7):e0254844. PubMed ID: 34280248
[TBL] [Abstract][Full Text] [Related]
12. Low skeletal muscle mass is a strong predictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap.
Ansari E; Chargi N; van Gemert JTM; van Es RJJ; Dieleman FJ; Rosenberg AJWP; Van Cann EM; de Bree R
Oral Oncol; 2020 Feb; 101():104530. PubMed ID: 31881447
[TBL] [Abstract][Full Text] [Related]
13. Validation of skeletal muscle mass assessment at the level of the third cervical vertebra in patients with head and neck cancer.
Bril SI; Chargi N; Wendrich AW; Wegner I; Bol GH; Smid EJ; de Jong PA; Devriese LA; de Bree R
Oral Oncol; 2021 Dec; 123():105617. PubMed ID: 34749251
[TBL] [Abstract][Full Text] [Related]
14. Locally advanced squamous cell carcinoma of the head and neck: CT texture and histogram analysis allow independent prediction of overall survival in patients treated with induction chemotherapy.
Zhang H; Graham CM; Elci O; Griswold ME; Zhang X; Khan MA; Pitman K; Caudell JJ; Hamilton RD; Ganeshan B; Smith AD
Radiology; 2013 Dec; 269(3):801-9. PubMed ID: 23912620
[TBL] [Abstract][Full Text] [Related]
15. CT-measured skeletal muscle mass used to assess frailty in patients with head and neck cancer.
Zwart AT; van der Hoorn A; van Ooijen PMA; Steenbakkers RJHM; de Bock GH; Halmos GB
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1060-1069. PubMed ID: 31134765
[TBL] [Abstract][Full Text] [Related]
16. Low skeletal muscle mass as predictor of postoperative complications and decreased overall survival in locally advanced head and neck squamous cell carcinoma: the role of ultrasound of rectus femoris muscle.
Galli A; Colombo M; Carrara G; Lira Luce F; Paesano PL; Giordano L; Bondi S; Tulli M; Mirabile A; De Cobelli F; Bussi M
Eur Arch Otorhinolaryngol; 2020 Dec; 277(12):3489-3502. PubMed ID: 32535862
[TBL] [Abstract][Full Text] [Related]
17. Interobserver agreement of skeletal muscle mass measurement on head and neck CT imaging at the level of the third cervical vertebra.
Bril SI; Wendrich AW; Swartz JE; Wegner I; Pameijer F; Smid EJ; Bol GH; Pothen AJ; de Bree R
Eur Arch Otorhinolaryngol; 2019 Apr; 276(4):1175-1182. PubMed ID: 30689037
[TBL] [Abstract][Full Text] [Related]
18. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients.
de Jong C; Chargi N; Herder GJM; van Haarlem SWA; van der Meer F; van Lindert ASR; Ten Heuvel A; Brouwer J; de Jong PA; Devriese LA; Huitema ADR; Egberts TCG; de Bree R; Deneer VHM
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1554-1564. PubMed ID: 35301821
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer.
Jung AR; Roh JL; Kim JS; Kim SB; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2019 Jul; 116():98-106. PubMed ID: 31185387
[TBL] [Abstract][Full Text] [Related]
20. Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy.
Cortellini A; Palumbo P; Porzio G; Verna L; Giordano AV; Masciocchi C; Parisi A; Cannita K; Ficorella C; Bozzetti F
Thorac Cancer; 2018 Dec; 9(12):1623-1630. PubMed ID: 30259689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
